|
End-of-day quote
Shanghai S.E.
2026-08-21
|
5-day change | 1st Jan Change | ||
| 17.66 CNY | -2.91% |
|
-1.40% | +0.23% |
| Apr. 24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
| Apr. 24 | Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4% | MT |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,307 | 37,585 | 28,359 | 17,151 | 20,066 | 20,112 | - | - |
| Change | - | 12.85% | -24.55% | -39.52% | 17% | 0.23% | - | - |
| Enterprise Value (EV) 1 | 32,838 | 36,233 | 27,369 | 15,778 | 16,831 | 16,593 | 16,102 | 15,694 |
| Change | - | 10.34% | -24.46% | -42.35% | 6.67% | -1.41% | -2.96% | -2.54% |
| P/E | 42.1x | 36.3x | 24.2x | 18.6x | 16.3x | 13.5x | 11.7x | 10.3x |
| PBR | 6.3x | 6.24x | 4.16x | 2.49x | 2.72x | 2.54x | 2.33x | 2.15x |
| PEG | - | 1.2x | 1.8x | -0.9x | 0.5x | 0.7x | 0.8x | 0.7x |
| Capitalization / Revenue | 1.99x | 1.77x | 1.16x | 0.65x | 0.73x | 0.67x | 0.61x | 0.55x |
| EV / Revenue | 1.96x | 1.71x | 1.12x | 0.6x | 0.61x | 0.55x | 0.49x | 0.43x |
| EV / EBITDA | 13.6x | 19.2x | 12.9x | 4.65x | 4.39x | 4.41x | 3.79x | 3.28x |
| EV / EBIT | 31.6x | 25.5x | 16.8x | 10.5x | 8.26x | 7.28x | 6.14x | 5.24x |
| EV / FCF | 117x | 13.1x | 19.7x | 9.51x | 3.44x | 16.4x | 7.88x | 6.41x |
| FCF Yield | 0.86% | 7.61% | 5.09% | 10.5% | 29.1% | 6.09% | 12.7% | 15.6% |
| Dividend per Share 2 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.49 | 0.9007 | 0.993 | 1.181 |
| Rate of return | 1.19% | 1.52% | 1.24% | 2.06% | 2.78% | 5.1% | 5.62% | 6.69% |
| EPS 2 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.08 | 1.304 | 1.505 | 1.717 |
| Distribution rate | 50% | 55% | 30.1% | 38.3% | 45.4% | 69.1% | 66% | 68.8% |
| Net sales 1 | 16,759 | 21,248 | 24,531 | 26,497 | 27,502 | 29,906 | 33,032 | 36,680 |
| EBITDA 1 | 2,408 | 1,883 | 2,119 | 3,395 | 3,833 | 3,761 | 4,251 | 4,791 |
| EBIT 1 | 1,041 | 1,421 | 1,632 | 1,501 | 2,038 | 2,278 | 2,621 | 2,993 |
| Net income 1 | 791.2 | 1,036 | 1,166 | 914.8 | 1,235 | 1,485 | 1,714 | 1,954 |
| Net Debt 1 | -469.2 | -1,352 | -989.8 | -1,373 | -3,236 | -3,519 | -4,010 | -4,418 |
| Reference price 2 | 29.24 | 33.00 | 24.90 | 15.06 | 17.62 | 17.66 | 17.66 | 17.66 |
| Nbr of stocks (in thousands) | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | 1,138,848 | 1,138,848 | - | - |
| Announcement Date | 4/27/22 | 4/27/23 | 4/28/24 | 4/25/25 | 4/23/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.55x | 0.55x | 4.41x | 5.1% | 2.99B | |
| 17.67x | 0.74x | 11.03x | -.--% | 15.73B | |
| 21.72x | 0.84x | 14.16x | 1.03% | 6.72B | |
| 16.65x | 0.75x | 7.8x | 2.24% | 6.36B | |
| 14.95x | 0.98x | 7.06x | 2.83% | 4.32B | |
| 14.56x | 1.25x | 7.64x | 5.52% | 3.24B | |
| 14.4x | 0.87x | 6.52x | 4.46% | 3.05B | |
| 30.9x | - | - | - | 2.4B | |
| 20.66x | 0.6x | 7.69x | 1.99% | 1.55B | |
| Average | 18.34x | 0.82x | 8.29x | 2.9% | 5.15B | |
| Weighted average by Cap. | 17.95x | 0.81x | 9.52x | 1.89% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
